A feasibility study of the Nativis Voyager

Publication Title

CNS Oncol

Authors

Michael Murphy
Anthony Dowling
Christopher Thien
Emma Priest
Donna Morgan Murray
Santosh Kesari, Department of Translational Neurosciences and Neurotherapeutics, Pacific Neuroscience Institute and John Wayne Cancer Institute at Providence Saint John's Health Center, Santa Monica, CA, USA.Follow

Document Type

Article

Publication Date

3-1-2019

Keywords

Nativis Voyager; brain cancer; clinical trial; electromagnetic fields; glioblastoma; medical device; recurrent GBM

Abstract

AIM: Evaluation of the Nativis Voyager

MATERIALS & METHODS: A total of 15 patients with rGBM were treated with one of two Voyager ultra-low radio frequency energy cognates: A1A or A2HU. Safety and clinical utility were assessed every 2-4 months.

RESULTS: Median overall survival was 8.04 months in the A1A arm and 6.89 months in the A2HU arm. No serious adverse events associated with Voyager were reported. No clinically relevant trends were noted in clinical laboratory parameters or physical exams.

CONCLUSION: The data suggest that the Voyager is safe and feasible for the treatment of rGBM.

Area of Special Interest

Neurosciences (Brain & Spine)

Area of Special Interest

Cancer

Specialty/Research Institute

Neurosciences

Specialty/Research Institute

Oncology